FDA — authorised 1 December 2022
- Application: NDA215814
- Marketing authorisation holder: RIGEL PHARMS
- Local brand name: REZLIDHIA
- Indication: CAPSULE — ORAL
- Status: approved
🇺🇸 Rezlidhia in United States
FDA authorised Rezlidhia on 1 December 2022
Marketing authorisations
FDA
- Status: approved
Rezlidhia in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is Rezlidhia approved in United States?
Yes. FDA authorised it on 1 December 2022; FDA has authorised it.
Who is the marketing authorisation holder for Rezlidhia in United States?
RIGEL PHARMS holds the US marketing authorisation.